[go: up one dir, main page]

WO2016019237A3 - Inhibiteurs de la tyrosine kinase de bruton - Google Patents

Inhibiteurs de la tyrosine kinase de bruton Download PDF

Info

Publication number
WO2016019237A3
WO2016019237A3 PCT/US2015/043102 US2015043102W WO2016019237A3 WO 2016019237 A3 WO2016019237 A3 WO 2016019237A3 US 2015043102 W US2015043102 W US 2015043102W WO 2016019237 A3 WO2016019237 A3 WO 2016019237A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
bruton
tyrosine kinase
methods
btk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/043102
Other languages
English (en)
Other versions
WO2016019237A2 (fr
Inventor
Wei Chen
Longcheng Wang
Zhaozhong J. Jia
James T. Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of WO2016019237A2 publication Critical patent/WO2016019237A2/fr
Publication of WO2016019237A3 publication Critical patent/WO2016019237A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés hétéroaryle contenant un groupe cyano qui sont utiles en tant qu'inhibiteurs des kinases. L'invention concerne également des procédés de synthèse de tels inhibiteurs et des méthodes d'utilisation de ces inhibiteurs dans le traitement de maladies.
PCT/US2015/043102 2014-07-31 2015-07-31 Inhibiteurs de la tyrosine kinase de bruton Ceased WO2016019237A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462031658P 2014-07-31 2014-07-31
US62/031,658 2014-07-31

Publications (2)

Publication Number Publication Date
WO2016019237A2 WO2016019237A2 (fr) 2016-02-04
WO2016019237A3 true WO2016019237A3 (fr) 2016-04-07

Family

ID=55218446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/043102 Ceased WO2016019237A2 (fr) 2014-07-31 2015-07-31 Inhibiteurs de la tyrosine kinase de bruton

Country Status (1)

Country Link
WO (1) WO2016019237A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3277677B9 (fr) 2015-03-30 2021-07-14 Mission Therapeutics Limited Composés 1-cyano-pyrrolidine utilisés comme inhibiteurs d'usp30
WO2016192074A1 (fr) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Inhibiteurs de la btk
MA43753A (fr) * 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
CN107383013B (zh) * 2016-05-16 2020-03-31 苏州信诺维医药科技有限公司 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物
WO2018001331A1 (fr) 2016-06-30 2018-01-04 杭州华东医药集团新药研究院有限公司 Dérivé d'imidazopyridinamine phényle et son utilisation
EP3492471B1 (fr) 2016-08-17 2020-12-02 Shenzhen TargetRx, Inc. Composé bicyclique fusionné pour inhiber l'activité de la tyrosine kinase
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
EP3642196B1 (fr) 2017-06-20 2022-08-17 Mission Therapeutics Limited Cyanopyrrolidines substituées présentant une activité en tant qu'inhibiteurs de dub
MX2020003671A (es) * 2017-10-06 2020-08-03 Forma Therapeutics Inc Inhibicion de peptidasa especifica de ubiquitina 30.
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
CN111018865B (zh) * 2019-10-17 2021-01-15 山东大学 1-取代苄基吡唑并嘧啶衍生物及其制备方法与应用
WO2021184154A1 (fr) * 2020-03-16 2021-09-23 Flash Therapeutics, Llc Composés pour le traitement ou l'inhibition de la récurrence d'une leucémie myéloïde aiguë
EP4132925A1 (fr) 2020-04-08 2023-02-15 Mission Therapeutics Limited N-cyanopyrrolidines ayant une activité en tant qu'inhibiteurs de l'usp30
US20230219939A1 (en) 2020-05-28 2023-07-13 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
US20230303547A1 (en) 2020-06-04 2023-09-28 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
MX2022015608A (es) 2020-06-08 2023-03-03 Mission Therapeutics Ltd Hexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilos con actividad como inhibidores de la peptidasa especifica de ubiquitina 30 (usp30).
CN114075190A (zh) * 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
CN114573586B (zh) * 2020-11-28 2023-11-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用
CN113968860B (zh) * 2021-11-05 2023-06-06 杭州医学院 一种可逆btk抑制剂及其合成方法和应用
EP4441044A1 (fr) 2021-12-01 2024-10-09 Mission Therapeutics Limited N-cyanopyrrolidines substituées ayant une activité en tant qu'inhibiteurs de l'usp30

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076921A1 (en) * 2006-09-22 2008-03-27 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20090286768A1 (en) * 2008-05-19 2009-11-19 Osi Pharmaceuticals, Inc. Substituted imidazopyr- and imidazotri-azines
WO2014068527A1 (fr) * 2012-11-02 2014-05-08 Pfizer Inc. Inhibiteurs de la tyrosine kinase de bruton

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076921A1 (en) * 2006-09-22 2008-03-27 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20090286768A1 (en) * 2008-05-19 2009-11-19 Osi Pharmaceuticals, Inc. Substituted imidazopyr- and imidazotri-azines
WO2014068527A1 (fr) * 2012-11-02 2014-05-08 Pfizer Inc. Inhibiteurs de la tyrosine kinase de bruton

Also Published As

Publication number Publication date
WO2016019237A2 (fr) 2016-02-04

Similar Documents

Publication Publication Date Title
WO2016019237A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
ZA202401324B (en) Tyrosine kinase inhibitors
WO2016196776A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2016004305A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2015195848A8 (fr) Inhibiteurs de ezh2 utilisables à des fins de traitement du lymphome
EP3481402A4 (fr) Composés, compositions et méthodes de traitement de maladie
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
WO2015112806A3 (fr) Macrocycles de diaryle en tant que modulateurs de protéines kinases
EP3265084A4 (fr) Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton
EP3484504A4 (fr) Composés, compositions et méthodes de traitement de maladie
WO2015193740A3 (fr) Combinaisons thérapeutiques d'un inhibiteur de la tkb, d'un inhibiteur de la pi3k et/ou d'un inhibiteur de la jak-2
PH12016501107A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
HK1252425A1 (zh) 用於治疗脱髓鞘疾病的三唑类药物
WO2016109217A3 (fr) Inhibiteurs de la btk
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
WO2015171558A3 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
EP3093023A4 (fr) Composition pharmaceutique pour le traitement du cancer et préparation pharmaceutique pour le traitement du cancer contenant ladite composition en tant que substance active
EP3337482A4 (fr) Formulations transdermiques pour l'administration de composés de berbérine et leur utilisation dans le traitement de maladies et de pathologies sensibles à la berbérine
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2016005174A (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
EP3820477A4 (fr) Composés, compositions et procédés pour le traitement d'une maladie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15827074

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15827074

Country of ref document: EP

Kind code of ref document: A2